The determination of additive effect and intraocular pressure lowering effects of 0.05% bromocriptine and 0.25% timolol.
It has been confirmed that topically applied bromocriptine has a satisfactory intraocular pressure (IOP) lowering effect without serious ocular or systemic side effects. We compared the IOP lowering effects of 0.05% bromocriptine and 0.25% timolol and determined whether they have an additive effect in lowering IOP in normal volunteers. In a double-blind, randomised, prospective, single-dose study, we measured IOP in 24 ocular normotensive subjects before (baseline) and 2, 4 and 6 hours after topical instillation of the following drugs: timolol and bromocriptine alone (n: 14), timolol+bromocriptine, timolol+placebo, bromocriptine+placebo (n: 10). Both bromocriptine and timolol have a significant IOP lowering effect (p < 0.01) compared with the baseline value during the study period. There were no significant differences in IOP lowering effect between timolol and bromocriptine at 2 and 4 hours (p > 0.05), but timolol was more efficacious than bromocriptine at 6 hours (p < 0.05). An additive effect in lowering IOP was not found. Although timolol and bromocriptine have no additive effect in lowering IOP, topically applied bromocriptine may be used in the treatment of glaucoma.
Elibol
O
O
Department of Ophthalmology, Cumhuriyet University, School of Medicine, Sivas, Turkey.
Güler
C
C
Arici
K
K
Topalkara
A
A
Demircan
S
S
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage*; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004357:Drug Synergism; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D012016:Reference Values; D012449:Safety; D013999:Timolol / Q000008:administration & dosage*; D014065:Tonometry, Ocular / Q000379:methods
D000319:Adrenergic beta-Antagonists; D018491:Dopamine Agonists; D009883:Ophthalmic Solutions; D001971:Bromocriptine; D013999:Timolol